VCAM1 and progressive multifocal leukoencephalopathy: VLA-4 interaction with its ligand VCAM-1 can be blocked by the monoclonal antibody natalizumab, which is used to treat multiple sclerosis but has been associated with the development of progressive multifocal leukoencephalopathy (PML)89.